MK-677 explained: what an oral growth hormone secretagogue actually does
TL;DR
- MK-677 is an oral small molecule that mimics ghrelin and raises growth hormone release from the pituitary.
- It is not a peptide and not FDA-approved, despite being investigated for sarcopenia research years ago.
- Convenience comes with tradeoffs: appetite increases, water retention, and fasting glucose changes are common.
What it is
MK-677, also called ibutamoren, is a non-peptide oral compound. It acts as a ghrelin receptor agonist (in plain English: it binds the same receptor that the hunger hormone ghrelin binds). That receptor is called GHSR-1a (in plain English: the growth-hormone secretagogue receptor on the pituitary and brain). When activated, the pituitary releases pulses of growth hormone, which then signals the liver to make IGF-1 (in plain English: insulin-like growth factor 1, the downstream messenger that drives most of growth hormone's effects on tissue). MK-677 is taken as a pill, usually once daily, which is why people often ask about it.
How it works
Think of the pituitary gland as a thermostat for growth hormone, and ghrelin as the finger that turns the dial up. Injectable peptides like sermorelin or ipamorelin push that dial through different doorways. MK-677 walks through the ghrelin doorway, in pill form. The effect is sustained, dose-dependent elevation of growth hormone and IGF-1, often with the side effect of feeling hungrier (because the same receptor controls appetite). Unlike injectable growth hormone, MK-677 keeps the body's own pulsatile release pattern intact, which is part of why it was studied.
Who asks about it
Men in their 40s and 50s researching growth-hormone peptides often run into MK-677 first because it is oral. The question is usually some version of, "If a pill does the same thing as an injection, why bother with needles?" That is a fair question. The answer is in the side-effect and monitoring profile.
What the research says
Murphy and colleagues (1998) showed that MK-677 sustained growth hormone and IGF-1 elevation over weeks in healthy adults. Nass and colleagues (Annals of Internal Medicine, 2008) studied MK-677 in older adults over two years and found increased lean mass associated with sustained IGF-1 elevation — alongside a measurable increase in fasting glucose and insulin resistance in some participants. These are human studies. The signal is consistent: the drug does what it claims to do, and the metabolic side effects are real.
What to know before considering it
MK-677 is not FDA-approved as a drug. It was investigated for sarcopenia and frailty and development was discontinued. It is widely sold through gray-market channels, where purity and labeling are inconsistent. Reported effects include increased appetite, water retention, mild edema, fasting glucose elevation, and insulin resistance signals — particularly in older adults. Anyone considering it should have baseline labs, a clinician involved, and a clear stop rule if glucose drifts.
The Halftime POV
Oral convenience is real. So are the metabolic tradeoffs. Injectable secretagogues like sermorelin and ipamorelin are better characterized in clinical use today. If MK-677 is on the table, it belongs in a monitored protocol with baseline and follow-up labs — not a self-directed experiment.
Related reading:
FAQ
Q: Is MK-677 a peptide? A: No. MK-677 is a small molecule. It acts on the same receptor as the peptide ghrelin, but its chemical structure is different.
Q: Does MK-677 increase growth hormone? A: Published research shows MK-677 raises growth hormone and IGF-1 in dose-dependent fashion when taken orally.
Q: Is MK-677 FDA-approved? A: No. MK-677 was studied for sarcopenia and frailty but never received FDA approval. It is sold gray-market.
Q: What are the main side effects of MK-677? A: Reported side effects in research include increased appetite, water retention, fasting glucose elevation, and insulin resistance signals in older adults.
Disclaimer
This article is educational and is not medical advice. Compounded medications are not FDA-approved. Clinical outcomes depend on individual factors and require physician evaluation. Results vary. Halftime Health is launching soon — join the waitlist to get updates.
Get updates
Halftime Health is launching soon. Join the waitlist for updates.
Sources
- Murphy MG, et al. "MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism." Journal of Clinical Endocrinology and Metabolism, 1998. https://pubmed.ncbi.nlm.nih.gov/9467583/
- Nass R, et al. "Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults." Annals of Internal Medicine, 2008. https://pubmed.ncbi.nlm.nih.gov/19075203/
- Smith RG. "Development of growth hormone secretagogues." Endocrine Reviews, 2005. https://pubmed.ncbi.nlm.nih.gov/15814848/
This article discusses compounds that are currently under FDA Category 2 review (see our FDA categorization explainer). These compounds are not currently part of Halftime Health's published protocol catalog. This article is provided for educational purposes only and does not constitute medical advice or an offer to sell.
Frequently asked questions
Is MK-677 a peptide?
No. MK-677 is a small molecule. It acts on the same receptor as the peptide ghrelin, but its chemical structure is different.
Does MK-677 increase growth hormone?
Published research shows MK-677 raises growth hormone and IGF-1 in dose-dependent fashion when taken orally.
Is MK-677 FDA-approved?
No. MK-677 was studied for sarcopenia and frailty but never received FDA approval. It is sold gray-market.
What are the main side effects of MK-677?
Reported side effects in research include increased appetite, water retention, fasting glucose elevation, and insulin resistance signals in older adults.
Keep reading
A licensed physician can build a protocol from your own labs.
Membership from $69/mo, including your onboarding panel. Each protocol is its own monthly subscription.